FOR IMMEDIATE RELEASE
BioStratum Announces JBC Publication on the Anti-Angiogenic Activity
of Type IV Collagen Non-Collagenous Domains - Angiocol™
Research Triangle Park, N.C., -- March 21, 2000-- BioStratum Incorporated,
the world leader in basal
In this paper, the non-collagenous domains of three of the six chains of type IV collagen are shown to possess potent anti-angiogenic activity, i.e. they inhibit new blood vessel growth. Administration of these non-collagenous domains, referred to as Angiocol™, is shown to dramatically inhibit capillary development and tumor growth in the well established CAM animal model system. Similar results have been seen in a mouse/human chimera animal model, which uses grafted human skin with implanted human tumors (unpublished results). BioStratum is currently scaling up the production of these potent anti-angiogenesis agents and will soon initiate their clinical evaluation.
Previously, BioStratum announced the issuance of US Patent #5,856,184
to the University of Kansas Medical Center on the anti-angiogenic and
anti-tumor activities of the non-collagenous domain of type IV collagen,
The initial discovery of this unique anti-angiogenic activity was made by Drs. Billy Hudson and Michael Sarras at the University of Kansas Medical Center, in collaboration with BioStratum Incorporated. Dr. Hudson has been studying the structure and function of type IV collagen for over 25 years, and is an internationally renowned expert in type IV collagen. He also discovered two of the six chains of type IV collagen.
"In studying the assembly and organization of type IV collagen into a
biologically active basal lamina, we discovered that the addition of the
non-collagenous domain of type IV collagen disrupted the process," said
Dr.Hudson. "Realizing the requirement for a functional basal lamina
"These domains are some of the most potent
"We are particularly excited about Angiocol™, because
Plans for Angiocol™ clinical trials include its use as an adjunctive
therapy in metastatic cancers for which few effective therapies are available,
including malignant melanoma and colorectal cancer. It is anticipated
that Angiocol™ will be administered in association with chemotherapy and/or
radiotherapy. The product will
BioStratum Incorporated, based in Research Triangle Park, N.C., is a privately held biotechnology company developing proprietary therapeutics based on scientific advances in type IV collagen, basal lamina, and related technologies. The company's drug candidates are directed against novel basal lamina extracellular targets involved in degenerative and invasive disease processes fundamental to kidney disease, diabetes and cancer. The company has also developed methods for the production of recombinant basal lamina proteins for use in wound repair and advanced tissue regeneration protocols.